New offerings include personalized panels for breast and lung cancer patients and nationwide availability of whole-genome testing for colon cancer.
Labcorp has expanded its molecular residual disease (MRD) testing portfolio with new offerings designed to help clinicians detect cancer recurrence earlier than traditional imaging methods.
The expanded portfolio includes Labcorp Plasma Detect ID, a whole-exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Labcorp Plasma Detect Genome, a whole-genome MRD test for stage III colon cancer.
Cancer recurrence rates remain significant across these cancer types. Approximately 35% of stage III colon cancer patients will experience recurrence after treatment, along with 10% to 40% of patients with stage I-III breast cancer, and 10% to 55% of patients with stage I–III non-small cell lung cancer.
MRD testing tracks a patient’s risk of cancer recurrence by detecting small traces of circulating tumor DNA (ctDNA) in a patient’s bloodstream following treatment. This can signal molecular recurrence months before clinical relapse appears on traditional imaging or causes symptoms.
Both Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome MRD tests can detect ctDNA down to a limit of detection (LOD95) of 0.005%. Earlier detection allows oncologists to tailor surveillance strategies and helps inform next steps.
“For patients who have completed cancer treatment with curative intent, ongoing monitoring is essential to understand their risk of recurrence,” says Shakti Ramkissoon, MD, PhD, vice president, medical lead for oncology at Labcorp, in a release. “By expanding the Labcorp Plasma Detect portfolio, we’re giving clinicians advanced tools to track molecular residual disease and detect recurrence risk earlier, supporting more personalized and proactive care, while increasing patient access to non-invasive testing options.”
Clinical Studies Support Utility
Labcorp has several ongoing and completed clinical studies that highlight the clinical utility of Labcorp Plasma Detect to track early disease progression, predict long-term outcomes, and identify residual cancer. Two peer-reviewed publications recently featured clinical studies of Labcorp Plasma Detect that focus on the test’s utility in patients diagnosed with diffuse pleural mesothelioma and head and neck cancer.
Data were also presented at the recent AMP 2025 Annual Meeting outlining the continued development of Labcorp Plasma Detect Genome MRD, adding to a growing body of research that supports MRD testing as a component of personalized cancer care.
ID 80414627 @ Alexey Novikov | Dreamstime.com
